Edition:
United Kingdom

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

7.59USD
15 Dec 2017
Change (% chg)

$0.28 (+3.90%)
Prev Close
$7.31
Open
$7.30
Day's High
$7.81
Day's Low
$7.23
Volume
89,503
Avg. Vol
53,829
52-wk High
$10.24
52-wk Low
$2.43

Latest Key Developments (Source: Significant Developments)

Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.71 MILLION COMMON SHARES PRICED AT $7.00PER SHARE.  Full Article

Dicerna Pharmaceuticals Files Preliminary Prospectus Supplement Related To A Potential Common Stock Offering
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL COMMON STOCK OFFERING - SEC FILING.  Full Article

Dicerna announces proposed public offering of common stock
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.DICERNA PHARMACEUTICALS INC - TO USE PROCEEDS FROM OFFERING FOR PRECLINICAL STUDIES & CLINICAL TRIALS.  Full Article

Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES FIRST HUMAN DOSED IN PHASE 1 CLINICAL TRIAL OF DCR-PHXC FOR TREATMENT OF ALL FORMS OF PRIMARY HYPEROXALURIA.DICERNA PHARMACEUTICALS - ANTICIPATES THAT HUMAN PROOF-OF-CONCEPT DATA FROM PHASE 1 TRIAL FOR DCR-PHXC WILL BE AVAILABLE IN SECOND HALF OF 2018.  Full Article

Dicerna Pharmaceuticals Q3 loss per share ‍$0.92
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Dicerna Pharmaceuticals Inc :Q3 2017 loss per share ‍$0.92.  Full Article

Boehringer, Dicerna collaborate to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Dicerna Pharmaceuticals Inc :Boehringer Ingelheim and Dicerna announce collaboration to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis (NASH).Dicerna Pharmaceuticals Inc - ‍under terms of agreement, Dicerna may receive more than $200 million from Boehringer Ingelheim​.Dicerna Pharmaceuticals Inc - ‍Dicerna is also eligible to receive royalties staggered up to double-digits on worldwide net sales​.  Full Article

Dicerna files clinical trial application for DCR-PHXC for phase 1 study in hyperoxaluria
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Dicerna Pharmaceuticals Inc : :Dicerna files clinical trial application for DCR-PHXC, the company’s most advanced GalXC™ product candidate, for phase 1 study in primary hyperoxaluria (ph).Dicerna Pharmaceuticals Inc - ‍company expects to initiate clinical dosing in Q1 2018​.Dicerna Pharmaceuticals Inc - ‍company plans to submit additional CTAS in other European countries later this year​.  Full Article

Dicerna Pharmaceuticals files for mixed shelf of up to $150 million
Thursday, 13 Oct 2016 

Dicerna Pharmaceuticals Inc :Files for mixed shelf of up to $150 million - SEC filing.  Full Article

Dicerna reports Q2 2016 financial results
Thursday, 4 Aug 2016 

Dicerna Pharmaceuticals Inc : Dicerna reports second quarter 2016 financial and operational results . Reiterates its expectation that it has sufficient cash to fund operations for at least next 12 months ; qtrly loss per share $0.75 .Q2 earnings per share view $-0.84 -- Thomson Reuters I/B/E/S.  Full Article

Dicerna Qtrly loss per share $0.76
Monday, 9 May 2016 

Dicerna Pharmaceuticals Inc : Qtrly loss per share $0.76 . Q1 earnings per share view $-0.86 -- Thomson Reuters I/B/E/S .Dicerna reports first quarter 2016 financial and operational results.  Full Article